The cooperation in biotechnology between Cuba and Brazil is one of the best performing areas in bilateral agreements between the two countries. This branch includes the development and marketing of products and technology transfer programs in which have been working for several years.
Patricia Paredes, scientific manager CIMAB SA, distributor of the Center of Molecular Immunology (CIM), explained about the binational experience that exists with human recombinant erythropoietin to treat anemia that accompanies chronic kidney disease (CKD).
The center has a floor dedicated to obtaining national developed bioproduct, covering all the needs of the Cuban health system and the only health system in Brazil.
The coming months the production of erythropoietin, called the greatest advance in the care of chronic kidney patients, should be taken independently in Brazil in a purpose-built factory, which is currently under implementation.
The drug was introduced in the Cuban medical practice 15 years ago, it has received more than 50 health records and has been approved in over 25 countries. It is also exported to Viet Nam, India and Latin American nations.
Moreover, Paredes said the CIM works together with several Brazilian companies in the study of compounds for cancer therapy.
He noted that one of them is Nimotuzumab, a humanized monoclonal antibody produced by the CIM, which happened in the South American country record for use in pediatric patients with brain gliomas. He also completed a phase II clinical trial with this antibody for advanced esophageal cancer.
She also commented that it’s being performed a multinational investigation with a therapeutic vaccine for malignant tumors -Racotumomab- and procedures are made to present another vaccine for cancer also known as CimaVax-EGF (both developed in the CIM).
These two vaccines are part of a portfolio of drugs that fall into the so-called support medicines, who are looking to reduce the harmful effects of radiation and chemotherapy, and targeting specific tumor targets, which are those that have more antitumor response, she said. (Prensa Latina)